BioArctic AB Class B · OMXSTO:BIOA_B

BioArctic AB Class B — Q4 2023 Earnings Presentation

19 slides from BioArctic AB Class B's earnings presentation, Feb 14, 2024

  1. Slide 1: Q4 Report October-December 2023

    Slide 1: Q4 Report October-December 2023

    Q4 Report October-December 2023 Stockholm, February 14, 2024 Gunilla Osswald, PhD, CEO Anders Martin-Löf, CFO BioArctic AB

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such

  3. Slide 3: BioArctic – a unique Swedish biopharma company

    Slide 3: BioArctic – a unique Swedish biopharma company

    BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders Focus on neurodegenerative disorders with large unmet medical need World-class research and development organization, collaborations with leading academic researchers and pharma companies

  4. Slide 4: Highlights in and after the quarter

    Slide 4: Highlights in and after the quarter

    Highlights in and after the quarter • New data at CTAD congress in October supporting subcutaneous formulation • Leqembi launched in Japan in December • Leqembi approved in China in January • EMA to convene a scientific advisory group to discuss lecanemab • BioArctic and Eisai have agreed on commerc

  5. Slide 5: Lecanemab is the first AD disease-modifying treatment to receive full approval globally

    Slide 5: Lecanemab is the first AD disease-modifying treatment to receive full approval globally

    Lecanemab is the first AD disease-modifying treatment to receive full approval globally, establishing new standard of care USA Japan EU China Rest of World FDA granted Leqembi Applications submitted in PMDA approval Marketing authorization Granted approval traditional approval and Canada, Great Brit

  6. Slide 6: Steady progress of the Leqembi U.S. launch

    Slide 6: Steady progress of the Leqembi U.S. launch

    Steady progress of the Leqembi U.S. launch • P&T1 committee Leqembi approvals obtained ■ Total IDNs with P&T approval ■ Ordered IDNs at ~70% of top 100 IDNs2 in the U.S., and ~55% have now started ordering Leqembi • ~4,0003 neurologists or AD specialists have established diagnostic and infusion path

  7. Slide 7: Leqembi long term penetration supported by simplified diagnosis and convenient treatment

    Slide 7: Leqembi long term penetration supported by simplified diagnosis and convenient treatment

    Leqembi long term penetration will be supported by simplified diagnosis and more convenient treatment as well as label expansion Blood biomarkers Blood biomarkers as a confirmatory test3 as a triage test2 Usage addition for maintenance (U.S.) US US Launch Indication expansion full SC5 formulation (A

  8. Slide 8: Q4 pipeline highlights

    Slide 8: Q4 pipeline highlights

    Q4 pipeline highlights Next generation Alzheimer treatments • Investment decision to progress BrainTransporter technology. Two candidate drugs (CD) nominated: • BAN2802 (undisclosed target with BT) • BAN2803 (PyroGlu Aβ Ab with BT) Preparing for Phase 2a in Parkinson’s disease • EXIST – Study focuse

  9. Slide 9: A broad project portfolio with a focus on neurodegenerative diseases

    Slide 9: A broad project portfolio with a focus on neurodegenerative diseases

    A broad project portfolio with a focus on neurodegenerative diseases Regulatory Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 & Market ALZHEIMER’S DISEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease2 Lecanemab (BAN2401) (AHEAD 3-45) Eisai1 Preclinical (asymptoma

  10. Slide 10: Financial Summary

    Slide 10: Financial Summary

    Financial Summary 10 BioArctic AB

  11. Slide 11: 2,000 patients on Leqembi treatment in January

    Slide 11: 2,000 patients on Leqembi treatment in January

    2,000 patients on Leqembi treatment in January with around four times as many waiting to begin treatment Number of patients on Leqembi treatment • Eisai stated that 2,000 patients on Trend line after treatment last week of January broader PET coverage initiated − ”Challenging” to reach 10,000 patien

  12. Slide 12: Leqembi royalties are growing fast

    Slide 12: Leqembi royalties are growing fast

    Leqembi royalties are growing fast BioArctic royalty including amounts to • Royalty rate of 9% on global net sales be passed on to LifeArc − Recorded royalty includes additional 1% on US sales and 1.5% 8 7.3 on ex-US sales that passes through to LifeArc 7 • US Q4 sales were $ 7.2 M but weekly sales

  13. Slide 13: Operating expenses for 2023 within guidance, operating profit SEK 253 M

    Slide 13: Operating expenses for 2023 within guidance, operating profit SEK 253 M

    Operating expenses for 2023 within guidance, operating profit SEK 253 M Net Revenues (SEK M) OPEX by item (SEK M) Operating Profit/Loss (SEK M) 120 301 393 104 96 90 100 86 78 80 132 131 218 209 61 50 60 48 40 11 20 4 4 2 3 -44 -46 -60 -78 0 -101 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 -20 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2

  14. Slide 14: Strong financial position going forward

    Slide 14: Strong financial position going forward

    Strong financial position going forward Cash Balance (SEK M) Cash Flow From Operating Net Result (SEK M) Activities (SEK M) 1 106 1 112 1 042 998 299 294 863 801 805 752 137 125 112 117 -44 -46 -58 -102 -87 -40 -46 -53 -58 -64 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2

  15. Slide 15: Upcoming news flow and closing remarks

    Slide 15: Upcoming news flow and closing remarks

    Upcoming news flow and closing remarks 15 BioArctic AB

  16. Slide 16: Upcoming news flow

    Slide 16: Upcoming news flow

    Upcoming news flow Q1 2024 Q2 2024 Q3 2024 Q4 2024 Congresses AD/PD Mar 5-9 AAIC, Jul 28 - Aug 1 CTAD, Oct 29 - Nov 1 Lecanemab Potential EU approval Launch in China Planned start of s.c. and maintenance of lecanemab Phase 2a with dosing US regulatory exidavnemab submissions New data on Potential CH

  17. Slide 17: In summary

    Slide 17: In summary

    In summary Leqembi now approved in the US, Our early pipeline Finances remain Japan and China with continues to progress solid sales starting to pick up 17 BioArctic AB

  18. Slide 18: BioArctic will create drugs that improve lives of patients

    Slide 18: BioArctic will create drugs that improve lives of patients

    ” BioArctic will, through world-leading innovative research, create drugs that improve the lives of patients with neurodegenerative diseases. 18 BioArctic AB

  19. Slide 19: IR team

    Slide 19: IR team

    IR team GUNILLA OSSWALD, CEO ANDERS MARTIN-LÖF, OSKAR BOSSON, VP CECILIA LANNEBO, CFO COMMUNICATIONS & IR DIRECTOR IR To subscribe to financial reports/press releases and for more information, please visit www.bioarctic.com Contact: Next Report: Oskar Bosson, Q4 Report VP Communications & IR Oct-Dec

Source: Internet Archive copy of bioarctic.se

More decks from BioArctic AB Class B

All 27 BioArctic AB Class B decks